Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
hVIVO PLC on Tuesday said it has secured a £13.1 million contract with an unnamed pharmaceutical client to develop an influenza B virus model.
hVIVO is a London-based specialist contract research organisation providing testing for infectious and respiratory vaccines.
It said a prerequisite virus manufacturing phase has already been completed, and a characterisation trial is due to begin in the fourth quarter of the year.
The charcaterisation study consists of administering a dose of influenza B to volunteers, and subject to successful completion, hVIVO will carry out a human challenge trial in the first half of 2024.
Revenue from this human challenge model development contract will be recognised throughout 2023 and 2024.
Chief Executive Officer Yamin Khan said: ‘This existing top five global pharmaceutical client will support the development of a new influenza B challenge model to potentially test its vaccine candidate, in turn furthering our industry leading position by broadening our library of human challenge models.’
Shares in hVIVO were up 3.0% at 15.81 pence each in London on Tuesday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.